Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910414 · ClinicalTrials.gov registry record · Phase 3
TARGET BP I Clinical Trial
A Phase 3 study of Hypertension, sponsored by Ablative Solutions.
- Active
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 5
- Study locations
NCT02910414: Active Phase 3 study of Hypertension, sponsored by Ablative Solutions.
NCT02910414 is a Phase 3 study of Hypertension that is active but no longer recruiting, run by Ablative Solutions. The registered enrollment target is 300 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910414, a Phase 3 study of Hypertension, is active but no longer recruiting, sponsored by Ablative Solutions.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation - no alcohol infusion). Subjects will be randomized in a 1:1 fashion to treatment versus sham control via central randomization.
Primary Outcome
The change in mean 24-hour ambulatory SBP from baseline to 3 months post-procedure
Conditions Studied
Interventions
- DRUG Dehydrated alcohol
- DEVICE Peregrine System Kit (Sham Procedure)
Study Locations (5)
North Carolina
- NC Heart and Vascular Research - Raleigh
- Wake Forest University Baptist Medical Center - Winston-Salem
Alabama
- Cardiology PC - Birmingham
Georgia
- Piedmont Heart Institute - Atlanta
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
What the registry record for NCT02910414 still lists
NCT02910414 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Dehydrated alcohol is the first listed.
NCT02910414 lists 5 locations in 4 states (North Carolina, Alabama, Georgia).
Frequently Asked Questions
What is clinical trial NCT02910414 about?
NCT02910414 is a clinical study titled "TARGET BP I Clinical Trial". The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation - no alcohol infusion). Subjects will be rando...
What is the current status of trial NCT02910414?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2019-07-22. Estimated completion is 2026-05.
What conditions does trial NCT02910414 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT02910414?
The interventions under investigation include: Dehydrated alcohol (DRUG), Peregrine System Kit (Sham Procedure) (DEVICE).
Who is sponsoring clinical trial NCT02910414?
This trial is sponsored by Ablative Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02910414 being conducted?
This trial has 5 study locations across Alabama, Georgia, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02910414's enrollment target sits among peer trials
300 170th of 470 higher than 291 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI